*MS Articles* Two MS articles-One about a new MS Drug

[Guest guest]

Former Pharmaceutical Sales Rep Reveals The Inside Secrets And

Deceptive Tactics

Used To Sell Dangerous Drugs

This is a very long article but interesting reading.

http://blog.healthliesexposed.com/?postid=28

Also:

http://www.redorbit.com/news/health/664621/seronos_oral_cladribine_for_the_trea\

tment_of_multiple_sclerosis_awarded/index.html?source=r_health

Serono's Oral Cladribine for the Treatment of Multiple Sclerosis

Awarded Fast Track Status By FDA

GENEVA, Switzerland, September 21 /PRNewswire-FirstCall/ -- Serono

(virt-x: SEO and NYSE: SRA) announced today that oral cladribine has

been designated a Fast Track product by the US Food and Drug

Administration (FDA). This designation covers patients with relapsing

forms of multiple sclerosis.

Serono's proprietary oral formulation of cladribine for the treatment

of multiple sclerosis is currently being evaluated in a multi-center,

multi-national Phase III study, CLARITY (CLAdRIbine Tablets Treating

MS OrallY) . It is a two-year, double-blind, placebo-controlled study

involving over 1,200 patients. Patient enrollment into this pivotal

trial is planned to be completed by the end of 2006.

" We are very pleased that oral cladribine has been designated a Fast

Track product, " said Ernesto Bertarelli, CEO of Serono. " As a leader

in multiple sclerosis, we are committed to providing new treatment

options that can further improve the quality of the lives of people

with this serious disease and our objective is to bring to them the

first oral disease modifying treatment. "

" Thanks to decades of research, there are injectible drugs available

to treat some forms of MS, but there is certainly a need for more and

even better therapies to treat all forms of the disease. Having an

effective oral therapy for MS would be a major step forward in

improving quality of life for people with MS, " said Dr. Richert,

Vice President, Research and Clinical Programs, at the National

Multiple Sclerosis Society.

Fast Track programs are designed to facilitate the development and

expedite the review of new drugs that are intended to treat serious or

life-threatening conditions and that demonstrate the potential to

address unmet medical needs. Under Fast Track designation oral

cladribine is eligible for Priority Review and FDA may consider for

review portions of the marketing application before the New Drug

Application (NDA) is completed.

About cladribine

Cladribine is a purine nucleoside analogue that interferes with the

behavior and the proliferation of certain white blood cells,

particularly lymphocytes, which are involved in the pathological

process of multiple sclerosis. Through its differentiated mechanism of

action, oral cladribine may offer an alternative option to patients

with multiple sclerosis.

About multiple sclerosis

Multiple sclerosis is a chronic, inflammatory condition of the nervous

system and is the most common, non-traumatic, neurological disease in

young adults. Multiple sclerosis affects approximately two million

people worldwide. While symptoms can vary, the most common symptoms of

multiple sclerosis include blurred vision, numbness or tingling in the

limbs and problems with strength and coordination. The relapsing forms

of multiple sclerosis are the most common.

Background material

For free B-roll, video and other content for Serono and its products,

please visit the Serono Media Center

http://www.thenewsmarket.com/Serono. You can download print-quality

images and receive broadcast-standard video digitally or by tape from

this site. Registration and video is free to the media.

Forward-looking statements

Some of the statements in this press release are forward looking. Such

statements are inherently subject to known and unknown risks,

uncertainties and other factors that may cause actual results,

performance or achievements of Serono S.A. and affiliates to be

materially different from those expected or anticipated in the

forward-looking statements. Forward-looking statements are based on

Serono's current expectations and assumptions, which may be affected

by a number of factors, including those discussed in this press

release and more fully described in Serono's Annual Report on Form

20-F filed with the U.S. Securities and Exchange Commission on

February 28, 2006. These factors include any failure or delay in

Serono's ability to develop new products, any failure to receive

anticipated regulatory approvals, any problems in commercializing

current products as a result of competition or other factors, our

ability to obtain reimbursement coverage for our products, the outcome

of any government investigations and litigation. Serono is providing

this information as of the date of this press release, and has no

responsibility to update the forward-looking statements contained in

this press release to reflect events or circumstances occurring after

the date of this press release.

About Serono

Serono is a global biotechnology leader. The Company has eight

biotechnology products, Rebif®, Gonal-f®, Luveris®, Ovidrel(R

)/Ovitrelle®, Serostim®, Saizen®, Zorbtive and Raptiva®.

In addition to being the world leader in reproductive health, Serono

has strong market positions in neurology, metabolism and growth and

has recently entered the psoriasis area. The Company's research

programs are focused on growing these businesses and on establishing

new therapeutic areas, including oncology and autoimmune diseases.

In 2005, Serono, whose products are sold in over 90 countries,

achieved worldwide revenues of US$2,586.4 million. Reported net loss

in 2005 was US$106.1 million, reflecting a charge of US$725 million

taken relating to the settlement of the US Attorney's Office

investigation of Serostim. Excluding this charge as well as other

non-recurring items, adjusted net income grew 28.4% to US$565.3

million in 2005. Bearer shares of Serono S.A., the holding company,

are traded on the virt-x (SEO) and its American Depositary Shares are

traded on the New York Stock Exchange (SRA).

Serono International S A

CONTACT: For more information, please contact: Corporate

MediaRelations: Tel: +41-22-739-36-00, Fax:

+41-22-739-30-85,http://www.serono.com/; Corporate Investor Relations:

Tel: +41-22-739-36-01,Fax: +41-22-739-30-22; Media Relations, USA:

Tel: +1-, Fax:+1-; Investor Relations, USA:

Tel: +1-, Fax:+1-, http://www.seronousa.com/